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ABSTRACT The peptide conformation in the context of a protein polypeptide chain is influenced by proximal 
amino acid residues. However, the mechanisms of this interference remain poorly understood. We studied the 
conformation of angiotensins 1, 2 and 3, which are produced naturally in a sequential fashion from a precursor 
protein angiotensinogen and contain an identical peptide core structure. Using the example of angiotensins 1, 
2 and 3, it was shown that similar amino acid sequences may have significant conformational differences in 
various molecules. In order to assess the conformational changes, we developed a panel of high-affinity mouse 
monoclonal antibodies against angiotensins 1, 2 and 3 and studied their cross-reactivity in indirect and competi-
tive ELISAs. It was found that the conformations of inactive angiotensin1 and the corresponding fragment of 
angiotensinogen are similar; the same is true for the conformations of active angiotensins 2 and 3, whereas the 
conformations of homologous fragments in the active and inactive angiotensins differ significantly.
KEYWORDS peptides; conformation; angiotensins; angiotensinogen; monoclonal antibodies.
ABBREVIATIONS Ang1 – human angiotensin 1; Ang2 – human angiotensin 2; Ang3 – human angiotensin 3; 
ELISA – enzyme-linked immunosorbent assay; PAG – polyacrylamide gel; Hsp70 – heat shock protein with a 
molecular mass of 70 kDa; Kd – dissociation constant.
INTRODUCTION
Since the appearance of the hybridoma technology in 
1975 [1], a large number of monoclonal antibodies to 
various substances have been obtained. Despite this, 
new antibodies are still highly sought; namely, antibod-
ies with particular properties, antibodies to particular 
epitopes and to newly discovered proteins and other or-
ganic and inorganic compounds. normally, it is possible 
to obtain new proteins only in limited amounts, and fre-
quently it is very difficult or even impossible to isolate 
them in their pure form with the natural conformation 
preserved. these kinds of proteins cannot be used for 
immunization to obtain antibodies; hence, in the major-
ity of cases, the only viable option is immunization with 
synthetic peptides corresponding to particular frag-
ments of the desired protein. Along with the apparent 
advantages, this approach also has a number of short-
comings: i.e., peptides, when found in proteins, have a 
significantly  lower degree of freedom than when they 
are in a free state. As a result, the antibodies against 
peptides are not always capable of binding to full-size 
proteins [2].
the oft-cited example of the structural differenc-
es between peptides found in their protein precursor 
and peptides in a free state is human angiotensinogen 
and its metabolites; i.e., angiotensins 1, 2 and 3. Angi-
otensin 1 (Ang1) is a prohormone that consists  of 10 
amino acid residues and is produced from angiotensino-
gen as a result of the cleavage of the n-terminal pep-
tide [3]. the Ang1 exhibits no physiological activity 
and plays the role of a substrate in the formation of 
angiotensins 2 and 3. Angiotensin 2 (Ang2) differs from 
angiotensin 1 by the absence of two c-terminal amino 
acid residues. Angiotensin 3 (Ang3) is shorter than an-
giotensin 2 by one n-terminal residue (Figure). Ang1 
contains the same amino acids as Ang2; however, Ang1 
is incapable of binding to the receptors of Ang2 and 
thereby cannot initiate effector functions [4]. the most 
likely causal factor behind this phenomenon is the con-
formational differences between angiotensins 1 and 2. 
to confirm this hypothesis, we obtained monoclonal 
antibodies against angiotensins 1, 2 and 3 and studied 
their cross-reactivity to various angiotensins and an-
giotensinogen.reSeArcH ArtIcLeS
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EXPERIMENTAL
In this work human recombinant angiotensinogen 
(“Sigma”, uSA), angiotensins 1, 2 and 3 (“Ameri-
can Peptide”, uSA), recombinant Hsp70 from Myco-
bacterium tuberculosis obtained in our laboratory [5], 
BALB/c mice, and the mouse myeloma cell line Sp2/0 
were used.
The Production of Monoclonal Antibodies 
against Angiotensins 1, 2, and 3
Mice were immunized in their hind paws with angi-
otensins conjugated with Hsp70: an adjuvant protein 
from M. tuberculosis, as described in [6]. the proce-
dure was carried out twice with an interval of two 
weeks with  a dosage of 100 µg of the conjugate per 
one immunization. the first immunization was per-
formed using Freund’s complete adjuvant and the sec-
ond   through Freund’s incomplete adjuvant. On the 
third day following the second immunization, popliteal 
lymph node cells were hybridized with sp2/0 myelo-
ma cells in accordance with the standard procedure 
[1]. the supernatants of the hybrids were tested by 
means of indirect [7] and competitive enzyme-linked 
immunosorbent assays (eLISAs) [8]; positive clones 
were cloned  2–4 times, monoclonal antibodies were 
produced in ascitic fluids of mice and were isolated 
by affine chromatography on protein G-sepharose [9]. 
the purity of the antibodies was controlled by elec-
trophoresis in 12% polyacrylamide gel as described in 
[10].
Characterization of Monoclonal Antibodies Produced
the specificity of the obtained antibodies was deter-
mined by means of indirect and competitive eLISAs 
[7, 8]. the affinity of the antibodies against each target 
was assessed via the measurement of the dissociation 
constant (Kd) as described in [11] by Klotz, with modifi-
cations made by Friguet [12].
RESULTS AND DISCUSSION
the human and mouse angiotensins 1, as well as angi-
otensins 2 and 3, have identical amino acid sequences 
[13]. In addition, angiotensins 2 and 3 exhibit physi-
ological activity and their introduction into the body 
at doses needed for immunization (10–50 µg/mouse) 
leads to a fatal outcome even in the case of intramus-
cular and subcutaneous injections. Altogether, it makes 
angiotensins extremely inconvenient immunogens; 
however, their conjugation with Hsp70, an adjuvant 
protein from M. tuberculosis, allowed to overcome the 
immunological tolerance and to eliminate the toxicity. 
As a result, we obtained monoclonal antibodies against 
each angiotensin.
the specificity of  each antibody produced was 
determined by enzyme-linked immunosorbent as-
say (Table 1). Indirect eLISA revealed interaction be-
tween the antibodies and the sorbed targets. In the 
aforementioned system,  part of the structural units 
of angiotensinogen and peptides is found inaccessible 
to antibodies and the other part is distorted. through 
the competitive eLISA, we established the interaction 
of the antibodies with the protein and peptides in the 
single-phase system, i.e., a solution; in turn, the de-
termination of the dissociation constants allowed us to 
quantitatively estimate the interaction force (Table 2).
the most affine antibody obtained against angi-
otensin 1, Angc11 (Kd = 1.3 × 10–10), almost does not 
bind to sorbed Ang1 and also interacts with angi-
otensins 2 and 3 in neither indirect nor competitive 
eLISA. At the same time, Angc11 recognizes angi-
otensinogen both in the sorbed form and in solution. All 
these factors indicate that either the epitope of this an-
tibody contains amino acid residues that detach when 
angiotensins 2 and 3 are formed, or that the structures 
of this fragment in Ang1, Ang2, and Ang3  differ to the 
extent that the antibody is only capable of binding  to 
Ang1.
      1        2        3       4     5       6       7       8        9      10      11     12     13   14
Angiotensinogen Asp - Arg - Val - Tyr - Ile - His - Pro - Phe - His - Leu - Leu - Val - Tyr-Ser- 
Angiotensin 1 Asp - Arg - Val - Tyr - Ile - His - Pro - Phe - His - Leu 
Angiotensin 2 Asp - Arg - Val - Tyr - Ile - His - Pro - Phe 
Angiotensin 3            Arg - Val - Tyr - Ile - His - Pro - Phe
Amino acid sequences of the precursors of angiotensin 2 and its metabolites.76 | ActA nAturAe |  VOL. 4  № 1 (12)  2012
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In contrast, the antibodies obtained as a result of the 
immunization with angiotensins 2 and 3 recognize only 
angiotensins 2 and 3, without making any difference be-
tween them in competitive analysis and preferring Ang2 
in indirect eLISA, regardless of which angiotensin im-
munization (second or third) is performed. the fact that 
angiotensin 2 was better recognized in indirect eLISA 
can be explained simply by its  superior ability  to sorb 
Ang2 than the shorter, less hydrophilic Ang3. none of 
the antibodies against Ang2 and Ang3 recognizes an-
giotensin 1 and the angiotensinogen in any mode of en-
zyme-linked immunosorbent assay. Despite this,  Ang1 
and angiotensinogen containing amino acid sequences 
are also found in the structures of angiotensins 2 and 3.
CONCLUSIONS
Summarizing the results, we can draw the following 
conclusions:
1. Angiotensin 1 in free state and in angiotensinogen 
has the same conformation;
2. the detachment of two amino acid residues from 
Ang1 changes the conformational structure of the en-
tire peptide; the produced angiotensin 2 has a different 
conformation than the conformation of the identical 
fragments in angiotensin 1 and angiotensinogen;
3. the detachment of one amino acid residue from 
angiotensin 2 does not significantly alter the confor-
mational structure of the peptide; the conformation 
of angiotensin 3 produced as a result is similar to the 
conformation of angiotensin 2 and differs completely 
from the conformation of the corresponding fragments 
in Ang1 and angiotensinogen; 
4. When short peptides are used for producing mono-
clonal antibodies against proteins, the probability of a 
Table 1. Interaction of antibodies with angiotensins 1, 2, and 3 and with angiotensinogen in indirect and competitive 
ELISAs
Immunogen Antibody
Indirect eLISA competitive eLISA
A-gen А1 А2 А3 A-gen А1 А2 А3
Аng 1
Ange9 - + - - - + - -
Angc9 + + - - + + ± ±
Angc11 + ± - - + + - -
Аng 2 AngIIe7 - - + ± - - + +
Аng 3
AngIII B7 - - + ± n.d. n.d. n.d. n.d.
AngIII F7 - - + ± n.d. n.d. n.d. n.d.
Table 2. Dissociation constants (Kd) of monoclonal anti-
bodies against angiotensins 1 and 2 with different targets
Antibody
Kd, M
A-gen Аng 1 Аng 2 Аng 3
Ange9 >10-5 4.7х10-7 >10-5 >10-5
Angc9 4.0х10-8 7.7х10-9 3.0х10-5 3.0х10-5
Angc11 1.25х10-8 1.3х10-10 5.5х10-6 2.3х10-5
AngIIe7 >10-5 >10-5 6.0х10-7 2.0х10-6
complete transformation of the protein antigenic deter-
minants synthesized in the form of peptides should be 
taken into account; peptides sorbed in solid phase can 
also have significant conformational differences from 
dissolved peptides with the same amino acid sequence.
the transformation of inactive angiotensin 1 and an-
giotensinogen into their active forms, Ang2 and Ang3, 
is accompanied by a significant conformational rear-
rangement of the corresponding fragments in peptide 
and protein molecules. 
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